Published in Proteome Sci on February 14, 2008
Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev (2014) 1.51
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem (2013) 1.34
Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol (2010) 1.30
Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol (2013) 1.24
The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One (2010) 1.23
Glutathione metabolism and Parkinson's disease. Free Radic Biol Med (2013) 1.20
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain (2012) 1.15
A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci (2013) 1.11
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (2013) 1.04
Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis (2008) 1.01
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration. Mol Neurobiol (2013) 0.91
Enrichment of single neurons and defined brain regions from human brain tissue samples for subsequent proteome analysis. J Neural Transm (Vienna) (2015) 0.85
Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther (2009) 0.83
Iron regulatory proteins increase neuronal vulnerability to hydrogen peroxide. Biochem Biophys Res Commun (2008) 0.82
Emerging candidate biomarkers for Parkinson's disease: a review. Aging Dis (2013) 0.82
Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration. J Neural Transm (Vienna) (2009) 0.80
Neuroscience and heart-brain medicine: the year in review. Cleve Clin J Med (2010) 0.80
Alterations in glutathione S-transferase pi expression following exposure to MPP+ -induced oxidative stress in the blood of Parkinson's disease patients. Parkinsonism Relat Disord (2011) 0.79
Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol (2010) 0.78
Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. PLoS One (2014) 0.78
Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease. J Neural Transm (Vienna) (2014) 0.77
Proteomics analysis of MPP+-induced apoptosis in SH-SY5Y cells. Neurol Sci (2010) 0.77
Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease. Transl Neurodegener (2014) 0.76
Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics (2016) 0.75
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration? Antioxidants (Basel) (2017) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Dopamine neuron agenesis in Nurr1-deficient mice. Science (1997) 5.40
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A (2005) 3.40
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A (1996) 2.88
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet (2005) 2.72
CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci (2001) 2.70
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet (1998) 2.65
Retinoid-binding proteins: mediators of retinoid action. Biochem J (2000) 2.64
Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem (2004) 2.46
Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. Free Radic Biol Med (2005) 2.23
Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab (2006) 2.16
Pathoanatomy of Parkinson's disease. J Neurol (2000) 2.16
Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord (1998) 2.12
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett (1982) 1.89
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol (1998) 1.82
Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J (1997) 1.61
High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci U S A (1994) 1.58
Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. Biochemistry (2006) 1.53
ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis (2003) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem (2005) 1.42
A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem (1995) 1.40
Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science (1998) 1.39
Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact (2003) 1.39
The pathogenesis of cell death in Parkinson's disease. Neurology (2006) 1.38
Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics (2004) 1.36
Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfate-polyacrylamide gels using a luminescent ruthenium complex. Electrophoresis (2000) 1.35
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Glutathione, iron and Parkinson's disease. Biochem Pharmacol (2002) 1.32
Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics (2006) 1.31
Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol (1994) 1.29
Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord (2003) 1.29
14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life (2005) 1.27
Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience (1993) 1.27
Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics (2006) 1.21
Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases. Pharmacogenet Genomics (2005) 1.18
Specific sorting of the a1 isoform of the V-H+ATPase a subunit to nerve terminals where it associates with both synaptic vesicles and the presynaptic plasma membrane. J Cell Sci (2003) 1.17
Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci (1997) 1.17
Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. Biochem J (1985) 1.16
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol (2005) 1.16
Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol (2005) 1.15
mu-crystallin is a mammalian homologue of Agrobacterium ornithine cyclodeaminase and is expressed in human retina. Proc Natl Acad Sci U S A (1992) 1.11
Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J Neurochem (1998) 1.11
"Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol Cell Proteomics (2005) 1.08
Parkinson's disease and other alpha-synucleinopathies. Clin Chem Lab Med (2001) 1.06
UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol (2006) 1.06
Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. Neurobiol Aging (2006) 1.05
Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease. Neurosci Lett (2003) 1.05
Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease. Trends Mol Med (2003) 1.00
Postmortem changes in the level of brain proteins. Exp Neurol (2001) 1.00
Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat (2000) 1.00
Parkinson's prevalence estimated by a state registry. Mov Disord (2004) 0.99
Galectin-1 induces astrocyte differentiation, which leads to production of brain-derived neurotrophic factor. Glycobiology (2003) 0.98
Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies. Am J Pathol (2002) 0.95
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord (2005) 0.92
Dihydropyrimidinase related protein-2 as a biomarker for temperature and time dependent post mortem changes in the mouse brain proteome. Proteomics (2003) 0.91
Decreased ferritin levels in brain in Parkinson's disease. J Neurochem (1990) 0.91
Biotransformation of methyl parathion by glutathione S-transferases. Toxicol Sci (2004) 0.90
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord (2005) 0.90
Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype. Biol Psychiatry (2003) 0.90
Molecular cloning and functional expression of rat liver glutathione-dependent dehydroascorbate reductase. J Biol Chem (1998) 0.89
Overexpression of glia maturation factor in C6 cells promotes differentiation and activates superoxide dismutase. Neurochem Res (1998) 0.89
In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci Lett (2006) 0.89
Glutathione and glucose-6-phosphate dehydrogenase deficiency can increase protein glycosylation. Free Radic Biol Med (1998) 0.88
S-adenosyl-L-homocysteine hydrolase in yeast: key enzyme of methylation metabolism and coordinated regulation with phospholipid synthesis. FEBS Lett (2004) 0.87
Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol Histopathol (2006) 0.86
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett (2001) 0.85
3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm (Vienna) (2002) 0.84
Annexin V labels apoptotic neurons following hypoxia-ischemia. Neuroreport (1997) 0.84
Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat Disord (2005) 0.84
Galectin-1 expression correlates with the regenerative potential of rubrospinal and spinal motoneurons. Neuroscience (2004) 0.83
The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal. Neurotox Res (2005) 0.83
Partial purification and properties of human brain aldehyde dehydrogenases. J Neurochem (1985) 0.82
The lack of annexin A7 affects functions of primary astrocytes. Exp Cell Res (2003) 0.80
Anti-AGEing defences against Alzheimer's disease. Biochem Soc Trans (2003) 0.80
Genetic polymorphisms of superoxide dismutase in Parkinson's disease. Mov Disord (2001) 0.79
Plasma homocysteine levels in pergolide-treated Parkinson disease patients. Clin Neuropharmacol (2004) 0.78
Crystal structure of human SH3BGRL protein: the first structure of the human SH3BGR family representing a novel class of thioredoxin fold proteins. Proteins (2005) 0.78
Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause. Mov Disord (1999) 0.76
[Postmortal diagnosis of Parkinson's disease]. Pathologe (2005) 0.76
Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease. J Neurol Neurosurg Psychiatry (1995) 0.76
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
ICAM-1 signaling in endothelial cells. Pharmacol Rep (2009) 3.06
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Decrease in dendritic cells in endomyocardial biopsies of human dilated cardiomyopathy. Eur J Heart Fail (2013) 1.43
The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J Cereb Blood Flow Metab (2008) 1.02
Two amino acid residues determine the low substrate affinity of human cationic amino acid transporter-2A. J Biol Chem (2003) 0.88
Uterine peristaltic activity and the development of endometriosis. Ann N Y Acad Sci (2004) 0.87
Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B⁺ tenascin-C and ED-A⁺ fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis. Int J Cardiol (2013) 0.86
Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int (2003) 0.86
Early glomerular alterations in genetically determined low nephron number. Am J Physiol Renal Physiol (2010) 0.83
N'-benzylidene-benzohydrazides as novel and selective tau-PHF ligands. J Alzheimers Dis (2011) 0.83
Impaired myocardial capillarogenesis and increased adaptive capillary growth in FGF2-deficient mice. Lab Invest (2006) 0.80
Effects of estrogens on cardiovascular structure in uninephrectomized SHRsp rats. Kidney Int (2005) 0.80
Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease. Cardiovasc Res (2002) 0.80
The use of rapid diagnostic test of procalcitonin serum levels for the postmortem diagnosis of sepsis. Forensic Sci Int (2008) 0.79
Myocyte loss in early left ventricular hypertrophy of experimental renovascular hypertension. Virchows Arch (2003) 0.79
Expression of endothelial intercellular adhesion molecule-1 is determined by genotype: effects on efficiency of leukocyte adhesion to human endothelial cells. Hum Immunol (2008) 0.79
Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed Pharmacother (2003) 0.78
Leucocyte adhesion under haemodynamic flow conditions. Methods Mol Biol (2010) 0.78
[Interpretation of elevated serum troponin levels in end stage renal disease - case 2/2010]. Dtsch Med Wochenschr (2010) 0.77
Bis(arylvinyl)pyrazines, -pyrimidines, and -pyridazines as imaging agents for tau fibrils and β-amyloid plaques in Alzheimer's disease models. J Med Chem (2012) 0.77
Influence of endothelin receptor antagonism on smooth muscle cell proliferation after chronic renal failure. J Cardiovasc Pharmacol (2004) 0.76
[Lichen sclerosus and squamous cell carcinoma of the vulva]. J Dtsch Dermatol Ges (2003) 0.76
Influence of standard haemodialysis treatment on transcription of human serum- and glucocorticoid-inducible kinase SGK1 and taurine transporter TAUT in blood leukocytes. Nephrol Dial Transplant (2005) 0.76
Posttransplant lymphoproliferative disorder in a kidney-pancreas transplanted recipient: simultaneous development of clonal lymphoid B-cell proliferation of host and donor origin. Am J Surg Pathol (2006) 0.75
Gene expression profiling on global cDNA arrays gives hints concerning potential signal transduction pathways involved in cardiac fibrosis of renal failure. Comp Funct Genomics (2003) 0.75
Design, synthesis and biological evaluation of trimethine cyanine dyes as fluorescent probes for the detection of tau fibrils in Alzheimer's disease brain and olfactory epithelium. ChemMedChem (2013) 0.75
Single coronary artery: a fatal R-I type. Forensic Sci Med Pathol (2012) 0.75
[79-year-old patient with pulmorenal syndrome]. Dtsch Med Wochenschr (2010) 0.75
The Case ∣ Odd-looking kidneys. Renal lymphangiomatosis. Kidney Int (2012) 0.75
2-Styrylindolium based fluorescent probes visualize neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem Lett (2012) 0.75
Synthesis of methoxy-X04 derivatives and their evaluation in Alzheimer's disease pathology. Neurodegener Dis (2013) 0.75
[Heart and kidney--only together they are strong. On the cardiorenal and renocardiac syndrome. Case 5/2011]. Dtsch Med Wochenschr (2011) 0.75
Fluorescent rhodanine-3-acetic acids visualize neurofibrillary tangles in Alzheimer's disease brains. Bioorg Med Chem (2013) 0.75
Sudden cardiac death due to catecholamine cardiomyopathy in anorexia nervosa. Resuscitation (2006) 0.75
Toxic myocarditis due to oral ingestion of hydrofluoric acid. Heart Lung Circ (2007) 0.75